Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations

Hematopoietic stem cell transplantation (HSCT) is effective therapy for patients with chronic myelogenous leukemia (CML) but is now mostly indicated for patients who develop resistance to tyrosine kinase inhibitors (TKIs), which can be associated with point mutations in BCR-ABL1. We reviewed the out...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Jabbour, Elias, Cortes, Jorge, Santos, Fabio P. S., Jones, Dan, O'Brien, Susan, Rondon, Gabriela, Popat, Uday, Giralt, Sergio, Kebriaei, Partow, Jones, Roy B., Kantarjian, Hagop, Champlin, Richard, de Lima, Marcos
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2011
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4186643/
https://ncbi.nlm.nih.gov/pubmed/21156844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-08-302679
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak